1
|
Lebrun F, Marty PA, Quintyn JC, Thariat J, Bailleul H. [High energy proton therapy for extraocular tumors, neurotrophic keratitis and functional consequence: A series of 3 cases]. J Fr Ophtalmol 2023; 46:841-850. [PMID: 37625997 DOI: 10.1016/j.jfo.2023.02.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2022] [Revised: 01/31/2023] [Accepted: 02/04/2023] [Indexed: 08/27/2023]
Abstract
INTRODUCTION High energy proton therapy (HEP) is a form of radiation therapy using protons for extraocular tumors. Its ballistic properties are theoretically advantageous, but the real impact on the surrounding ocular tissues during cerebral and ENT irradiation is poorly documented. We describe three consecutive patients with corneal damage following such irradiation. MATERIALS/METHODS Post-proton therapy neurotrophic keratitis (NK) is defined as corneal hypo/anesthesia responsible for an alteration of corneal trophicity and graded according to the Mackie classification, in terms of a prospective ophthalmological follow-up protocol for all patients with extraocular tumors treated with HEP. RESULTS Among 193 patients treated with HEP between 2018 and 2021 for extraocular tumors, three patients developed severe neurotrophic keratitis, i.e. 1.6% of treated patients. According to the Mackie classification, the three patients showed grade 3 NK less than one year after the conclusion of their HEP. These three patients underwent amniotic membrane grafting. They were placed on autologous serum eye drops. Two of the three patients had to be eviscerated. The dose to the cornea was greater than 50 Gray (Gy)_Relative biological effectiveness (RBE) in the three cases. DISCUSSION The diagnosis and etiological origin of neurotrophic keratitis are often difficult to establish. In these cases, the imputability of radiation therapy, proton therapy in our cases, in the development of neurotrophic keratitis was plausible based on the dosimetry of the patients, all of whom had anterior tumors with a poor prognosis requiring high tumoricidal doses. CONCLUSION Further studies to establish the impact of proton therapy on corneal sensitivity are necessary. However, this feedback and the multidisciplinary management of tumors can help to limit the risk of some complications of radiation therapy. Early diagnosis allows for appropriate management and could possibly minimize the anatomical and functional ocular complications of neurotrophic keratitis.
Collapse
Affiliation(s)
- F Lebrun
- Centre hospitalier universitaire de Caen-Normandie, avenue de la Côte-de-Nacre, 14033 Caen cedex 9, France.
| | - P-A Marty
- Centre hospitalier universitaire de Caen-Normandie, avenue de la Côte-de-Nacre, 14033 Caen cedex 9, France
| | - J-C Quintyn
- Centre hospitalier universitaire de Caen-Normandie, avenue de la Côte-de-Nacre, 14033 Caen cedex 9, France
| | - J Thariat
- Laboratoire de Physique Corpusculaire/IN2P3-CNRS UMR 6534-ARCHADE, Unicaen-Université de Normandie, Centre François-Baclesse, 14000 Caen, France
| | - H Bailleul
- Hôpital privé de la Baie-d'Avranches, 50300 Avranches, France
| |
Collapse
|
2
|
Rabhi N, Batani D, Boutoux G, Ducret JE, Jakubowska K, Lantuejoul-Thfoin I, Nauraye C, Patriarca A, Saïd A, Semsoum A, Serani L, Thomas B, Vauzour B. Calibration of imaging plate detectors to mono-energetic protons in the range 1-200 MeV. THE REVIEW OF SCIENTIFIC INSTRUMENTS 2017; 88:113301. [PMID: 29195357 DOI: 10.1063/1.5009472] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Responses of Fuji Imaging Plates (IPs) to proton have been measured in the range 1-200 MeV. Mono-energetic protons were produced with the 15 MV ALTO-Tandem accelerator of the Institute of Nuclear Physics (Orsay, France) and, at higher energies, with the 200-MeV isochronous cyclotron of the Institut Curie-Centre de Protonthérapie d'Orsay (Orsay, France). The experimental setups are described and the measured photo-stimulated luminescence responses for MS, SR, and TR IPs are presented and compared to existing data. For the interpretation of the results, a sensitivity model based on the Monte Carlo GEANT4 code has been developed. It enables the calculation of the response functions in a large energy range, from 0.1 to 200 MeV. Finally, we show that our model reproduces accurately the response of more complex detectors, i.e., stack of high-Z filters and IPs, which could be of great interest for diagnostics of Petawatt laser accelerated particles.
Collapse
Affiliation(s)
- N Rabhi
- CELIA (Centre Lasers Intenses et Applications), Université Bordeaux, CNRS, CEA, UMR 5107, F-33405 Talence, France
| | - D Batani
- CELIA (Centre Lasers Intenses et Applications), Université Bordeaux, CNRS, CEA, UMR 5107, F-33405 Talence, France
| | - G Boutoux
- CELIA (Centre Lasers Intenses et Applications), Université Bordeaux, CNRS, CEA, UMR 5107, F-33405 Talence, France
| | - J-E Ducret
- CELIA (Centre Lasers Intenses et Applications), Université Bordeaux, CNRS, CEA, UMR 5107, F-33405 Talence, France
| | - K Jakubowska
- CELIA (Centre Lasers Intenses et Applications), Université Bordeaux, CNRS, CEA, UMR 5107, F-33405 Talence, France
| | | | - C Nauraye
- Institut Curie, Centre de Protonthérapie d'Orsay-Campus Universitaire, Bâtiment 101, 15, rue Georges Clémenceau, F-91898 Orsay Cedex, France
| | - A Patriarca
- Institut Curie, Centre de Protonthérapie d'Orsay-Campus Universitaire, Bâtiment 101, 15, rue Georges Clémenceau, F-91898 Orsay Cedex, France
| | - A Saïd
- Institut de Physique Nucléaire d'Orsay, 15, rue Georges Clémenceau, F-91405 Orsay Cedex, France
| | - A Semsoum
- Institut de Physique Nucléaire d'Orsay, 15, rue Georges Clémenceau, F-91405 Orsay Cedex, France
| | - L Serani
- Centre d'Etudes Nucléaires de Bordeaux Gradignan, Université de Bordeaux, UMR 5797 CNRS/IN2P3, 19, Chemin du Solarium, Gradignan F-33175, France
| | - B Thomas
- Centre d'Etudes Nucléaires de Bordeaux Gradignan, Université de Bordeaux, UMR 5797 CNRS/IN2P3, 19, Chemin du Solarium, Gradignan F-33175, France
| | - B Vauzour
- CEA DAM DIF, F-91297 Arpajon, France
| |
Collapse
|
4
|
Abstract
There have been considerable technical improvements in radiation therapy for the past two decades. In children affected with cancer, these have been likely overshadowed by concommittant major chemotherapy-based advances, and at least in part ignored and misused. This article outlines principles, technological requirements, and clinical applications of innovations that aim at improving ballistical selectivity (such as conformal, intensity modulation, stereotactic photons, charged particles, and intraoperative therapies), as well as at influencing tumors and normal tissues sensitivity to radiations (such as high LET particles, and altered fractionations).
Collapse
Affiliation(s)
- Jean-Louis Habrand
- Pediatric Unit, Department of Radiation Oncology, Institut Gustave-Roussy, Villejuif, France.
| | | | | |
Collapse
|
5
|
Habrand JL, Haie-Meder C, Rey A, Mammar H, Pontvert D, Gaboriaud G, Couanet D, Lenir C, Valinta D, Ferrand R, Boisserie G, Beaudré A, Kerody K, Mazal A, Dupouy N, Bonomi M, Mazeron JJ. [Radiotherapy using a combination of photons and protons for locally aggressive intracranial tumors. Preliminary results of protocol CPO 94-C1]. Cancer Radiother 1999; 3:480-8. [PMID: 10630161 DOI: 10.1016/s1278-3218(00)88255-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE From October 1993 through July 1998, 48 assessable adult patients with non-resectable aggressive intracranial tumors were treated by a combination of high dose photon + proton therapy at the Centre de Protonthérapie d'Orsay. PATIENTS AND METHODS Grade 1 and 4 gliomas were excluded. Patients benefited from a 3D dose calculation based on high-definition CT and MRI, a stereotactic positioning using implanted fiducial markers and a thermoplastic mask. Mean tumor dose ranged between 63 and 67 Gy delivered in five weekly sessions of 1.8 Gy in most patients, according to the histological types (doses in Co Gy Equivalent, with a mean proton-RBE of 1.1). RESULTS With a median 18-month follow-up (range: four-58 months), local control in tumors located in the envelopes and in the skull base was 97% (33/34), and in parenchymal tumors, 43% (6/14) only. Two patients (5%) presented with a clinically severe radiation-induced necrosis (temporal lobe and chiasm). CONCLUSION In our experience, high-dose radiation combining photons and protons is a safe and highly efficient procedure in selected malignancies of the skull base and envelopes.
Collapse
|
6
|
Abstract
'Conformal radiotherapy' is the name fixed by usage and given to a new form of radiotherapy resulting from the technological improvements observed during, the last ten years. While this terminology is now widely used, no precise definition can be found in the literature. Conformal radiotherapy refers to an approach in which the dose distribution is more closely 'conformed' or adapted to the actual shape of the target volume. However, the achievement of a consensus on a more specific definition is hampered by various difficulties, namely in characterizing the degree of 'conformality'. We have therefore suggested a classification scheme be established on the basis of the tools and the procedures actually used for all steps of the process, i.e., from prescription to treatment completion. Our classification consists of four levels: schematically, at level 0, there is no conformation (rectangular fields); at level 1, a simple conformation takes place, on the basis of conventional 2D imaging; at level 2, a 3D reconstruction of the structures is used for a more accurate conformation; and level 3 includes research and advanced dynamic techniques. We have used our personal experience, contacts with colleagues and data from the literature to analyze all the steps of the planning process, and to define the tools and procedures relevant to a given level. The corresponding tables have been discussed and approved at the European level within the Dynarad concerted action. It is proposed that the term 'conformal radiotherapy' be restricted to procedures where all steps are at least at level 2.
Collapse
|
7
|
Desjardins L, Levy C, d'Hermies F, Frau E, Schlienger P, Habrand JL, Mammar H, Schwartz L, Mazal A, Delacroix S, Nauraye C, Ferrand R, Asselain B. [Initial results of proton therapy in choroidal melanoma at the d'Orsey Center for Proton Therapy; the first 464 cases]. Cancer Radiother 1997; 1:222-6. [PMID: 9295876 DOI: 10.1016/s1278-3218(97)89768-5] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
PURPOSE Retrospective analysis of the treatment of choroidal melanoma with protontherapy at the Centre de protonthérapie d'Orsay, France. PATIENTS AND METHODS Between September 1991 and September 1995, 612 patients presenting with choroidal melanoma were treated by protontherapy in Orsay. Following initial management of the first 464 patients, results were analyzed, as were results after a 1-year follow-up for 305 patients, a 2-year follow-up for 169 patients, and a 3-year follow-up for 59 patients. RESULTS Univariate analysis showed that the actuarial local recurrence rate was 5%, the 3-year survival rate 88%, and the overall metastasic rate 5%. The initial tumor volume was the most significant predictive factor for visual results and metastases. Multivariate analysis revealed that visual results were significantly related to the initial tumor volume, initial retinal detachment, and total dose delivered to the optic nerve and macula. CONCLUSION Protontherapy of choroidal melanoma allows in most cases conservation of the eye without modification of survival. Visual results mainly depend on the site and size of the tumor.
Collapse
|